Screening model of anti-breast cancer tumor drug

A breast cancer tumor and tumor drug technology, which is applied in the field of anti-breast cancer tumor drug screening models, can solve the problems of complex construction of anti-breast cancer tumor screening drug models, insufficient clinical applicability, and excessive time, so as to shorten the drug efficacy. The time required for the experiment, reducing the cost of clinical experiments, and the effect of high success rate

Pending Publication Date: 2019-03-22
苏州致诺优生物医学有限公司
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Aiming at the problems of complex construction, long time, high cost and insufficient clinical applicability of the existing anti-breast cancer tumor screening drug models, the present invention provides a screening model for anti-breast cancer tumor drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Screening model of anti-breast cancer tumor drug
  • Screening model of anti-breast cancer tumor drug
  • Screening model of anti-breast cancer tumor drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Example 1: Establishment of Pathological Model of Mouse Breast Cancer Tumor

[0031] 1. Preparation of hollow fiber reactor

[0032] refer to figure 1 , the hollow fiber reactor includes a plurality of hollow fibers 1 arranged in parallel, and a plurality of holes 2 are distributed on the surface of each hollow fiber tube. The material of the hollow fiber filaments used in the hollow fiber reactor is polypropylene or polychlorene, and the hollow fiber The diameter of the tube is 70-100 μm, the wall thickness is 2-4 μm, the length is 3-5 cm, the diameter of the hole is 100-300 nm, and 180 hollow fiber reactors are used in the experiment, and the surface of the hollow fiber reactor is modified with acetic acid plasma 40 minutes, and sterilized with UV light for 20 minutes to ensure that the cells are in a sterile state.

[0033] 2. Establishment of mouse breast cancer tumor model

[0034] 2.1 Establishment of a general breast cancer tumor cell model

[0035] Breast ca...

Embodiment 2

[0038]Embodiment 2: Establish the screening model of anti-breast cancer drug

[0039] 1. Experimental grouping

[0040] The 20 mice of the general breast cancer tumor model were divided into MCF blank group, MCF10A blank group, MCF administration group, and MCF10A administration group, with 5 mice in each group. The mice in MCF blank group and MCF10A blank group were not given anticancer drugs, and the mice in MCF treatment group and MCF10A treatment group were given Doxorubicin (DOX) drug.

[0041] The 15 mice of the pathogenic breast cancer tumor model were divided into control group, AC-T group and EC-T group, with 5 mice in each group. AC-T is the abbreviation for the combined anticancer drug Doxorubicin (A), Cyclophosphamide and Paclitaxel (T), and EC-T is the abbreviation for the combination of Epirubicin (E), Cyclophosphamide (C) and Paclitaxel (T).

[0042] 2. Screening model for anti-breast cancer drugs

[0043] In 20 mice of general breast cancer tumor model, the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
thicknessaaaaaaaaaa
lengthaaaaaaaaaa
Login to view more

Abstract

The invention discloses a screening model of an anti-breast cancer tumor drug. The screening model is constructed by the following specific steps: 1) modifying the surface of a hollow fiber reactor byusing acetic acid plasma, and sterilizing; 2) separating a breast cancer tumor single cell; 3) implanting the breast cancer tumor single cell in the hollow fiber reactor, and performing cell attachment culture; 4) determining a target drug, using a health mouse as an administration object, taking the hollow fiber reactor and implanting in the back of the mouse, after 24 h, establishing a mouse breast cancer tumor pathological model; 5) applying the target drug to the mouse breast cancer tumor pathological model, administrating once every 1-2 days, and constructing the screening model of the anti-breast cancer tumor drug. The screening model is capable of rapidly performing efficacy evaluation of the anti-breast cancer tumor drug, greatly shortening time needed by a pharmacological experiment of a traditional mouse xenograft transplantation model, wherein the time does not exceed 20 days from the experiment to a result, and reducing clinical experiment cost, and is easy to popularize.

Description

technical field [0001] The invention relates to the field of drug efficacy screening, in particular to a screening model for anti-breast cancer drugs. Background technique [0002] Breast cancer is the most common type of cancer in women, and the mortality rate of terminal cancer patients is relatively high. The reason is that there is no better treatment method other than targeted drugs, and chemotherapy drugs are less effective due to individual differences. high. Therefore, the demand for personalized precision medicine for patients is becoming more and more urgent. On the one hand, individualized precision medicine improves the accuracy of treatment, and on the other hand, it can effectively reduce the randomness and blindness of patients' medication, thereby reducing the harm of patients' medication. In recent years, the patient-derived xenograft model (PDX model) has been widely used in precision medicine as an animal model highly correlated with clinical patient dru...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N5/09C12Q1/02
CPCC12N5/0693G01N33/5011
Inventor 赖俊凯陈仲奇陈献堂赵美玲
Owner 苏州致诺优生物医学有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap